INNODIA is a consortium involving 33 academic from countries across Europe, industries and charitable organisations. The overarching aims of INNODIA are to advance our ability to predict, stage and evaluate the progression of Type 1 Diabetes (T1D). Like many EU projects, these goals of INNODIA will be achieved through a collaborative approach across a series of work streams called ‘work-packages’.
Three INNODIA work-packages – the Clinical Observational Study (Prof. David Dunger/Cambridge University); the Search for Biomarkers (Prof. Mark Peakman/Kings College, London) and the Design of Interventional Studies (Dr Adrian Mander/Cardiff University), are being led or co-led by researchers in the UK who are experts in their respective field. Additionally, Professor David Dunger has a central role in the overall delivery of the project which he co-coordinates with Professor Chantal Mathieu from the University of Leuven (Belgium).
The Clinical Observational Study’s main objective is to investigate the relationship between changes in β-cell function, immune profiles, genetic and environmental factors in newly diagnosed T1D patients and T1D family members at increased risk for the development of T1D. The Department of Paediatrics, University of Cambridge is coordinating this work package and both Cambridge University Hospitals NHS Foundation Trust and University of Cambridge sponsor the study.
The recruitment of participants involves 15 INNODIA partners from 10 different countries and is managed by Dr Sylvaine Bruggraber at the University of Cambridge.
Cambridge site Principal investigator
Clinical observational studies UK coordinator University of Cambridge
Screening: autoantibody positive participants will be referred to other sites for follow-up
Participant identification: eligible participants will be referred to other sites for visits
*ideally within 3 months of receiving the autoantibody results
The project received funding under the grant agreement n° 115797 (INNODIA) under the Joint Initiative Innovative Medicines Initiative 2 (www.imi.europa.eu). It was approved in November 2015 and launched in January 2016. The joint initiative is supported by the European Union’s Horizon 2020 research and innovation program, the European Federation of Pharmaceutical Industries and Associations (EFPIA), the Juvenile Diabetes Research Foundation (JDRF) and the Leona M. and Harry B. Helmsley Charitable Trust.
The clinical observational study has been reviewed by an independent research Ethics committee and is sponsored by Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge